Highlights of This Issue 2547

REVIEW

2549  It's About Time: Lessons for Solid Tumors from Chronic Myelogenous Leukemia Therapy
Jason R. Westin and Razelle Kurzrock

THERAPEUTIC DISCOVERY

2556  Restoration of miR-200c to Ovarian Cancer Reduces Tumor Burden and Increases Sensitivity to Paclitaxel
Diana M. Cittelly, Irina Dimitrova, Erin N. Howe, Dawn R. Cochrane, Annie Jean, Nicole S. Spoelstra, Miriam D. Post, Xian Lu, Russell R. Broaddus, Monique A. Spellman, and Jennifer K. Richer

2558  Dual Systemic Tumor Targeting with Ligand-Directed Phage and Grp78 Promoter Induces Tumor Regression
Azadeh Kia, Justyna M. Przystal, Nastasia Nianiaris, Nicholas D. Mazarakis, Paul J. Mintz, and Amin Hajitou

2576  DLL4-Fc, an Inhibitor of DLL4-Notch Signaling, Suppresses Liver Metastasis of Small Cell Lung Cancer Cells through the Downregulation of the NF-κB Activity

PRECLINICAL DEVELOPMENT

2600  RSK2Ser227 at N-Terminal Kinase Domain Is a Potential Therapeutic Target for Multiple Myeloma
Yuji Shimura, Junya Kuroda, Masaki Ri, Hisao Nagoshi, Mio Yamamoto-Sugitani, Tsutomu Kobayashi, Miki Kiyota, Ryuko Nakayama, Shinsuke Mizutani, Yoshiaki Chinen, Natsumi Sakamoto, Yosuke Matsumoto, Shigeo Horiiike, Yukimasa Shiotsu, Shinsuke Iida, and Masafumi Taniwaki

2608  Sorafenib-Mediated Targeting of the AAA ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death
Peng Yi, Arisa Higa, Said Taojii, Mariana G. Bexiga, Esther Marza, Daniela Arma, Claire Castain, Brigitte Le Bail, Jeremy C. Simpson, Jean Rosenbaum, Charles Balbaid, Paulette Bioulac-Sage, Jean-Frédéric Blanc, and Eric Chevet

2620  Contrary Regulation of Bladder Cancer Cell Proliferation and Invasion by Dexamethasone-Mediated Glucocorticoid Receptor Signals
Yichun Zheng, Koji Izumi, Yi Li, Hitoshi Ishiguro, and Hiroshi Miyamoto

2633  Targeting KRAS-Mutant Non-Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib
Jaime Acquaviva, Donald L. Smith, Jim Sang, Julie C. Friedland, Suqin He, Manuel Sequeira, Chaohua Zhang, Yumiko Wada, and David A. Proia

2644  BMS-754807, a Small-Molecule Inhibitor of Insulin-like Growth Factor-1 Receptor/Insulin Receptor, Enhances Gemcitabine Response in Pancreatic Cancer
Niranjan Awasthi, Changhua Zhang, Winston Ruan, Margaret A. Schwarz, and Roderich E. Schwarz

2654  Targeting the Inhibitor of Apoptosis Proteins as a Novel Therapeutic Strategy in Medulloblastoma
Joanna Keating, Maria Tsoli, Andrew R. Hallahan, Wendy J. Ingram, Michelle Haber, and David S. Ziegler
Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens
Matthias Friedrich, Tobias Raum, Ralf Lutterbuese, Markus Voelkel, Petra Deegen, Doris Rau, Roman Kischel, Patrick Hoffmann, Christian Brandl, Joachim Schuhmacher, Peter Mueller, Ricarda Finnern, Melanie Fuerget, Dieter Zof, Jerry W. Slootstra, Patrick A. Baue, Benno Rattel, and Peter Kufer

Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production

Development of Gene Expression–Based Score to Predict Sensitivity of Multiple Myeloma Cells to DNA Methylation Inhibitors
Jerome Moreaux, Thierry Re, Wim Leonard, Jean-Luc Veyrune, Guilhem Requinand, Hartmut Goldschmidt, Dirk Hose, and Bernard Klein

Inhibiting Aurora Kinases Reduces Tumor Growth and Suppresses Tumor Recurrence after Chemotherapy in Patient-Derived Triple-Negative Breast Cancer Xenografts
Angela Romanelli, Anderson Clark, Franc Assayag, Sophie Chateau-Joubert, Marie-France Poupon, Jean-Luc Servelay, Jean-Jacques Fontaine, Xiaohong Liu, Edward Spooner, Samantha Goodstal, Patricia de Cremoux, Ivan Bièche, Didier Decaudin, and Elisabetta Marangoni

SPOTLIGHT ON CLINICAL RESPONSE
Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine
James S. Wilmott, Varsha Tembe, Julie R. Howle, Raghwa Sharma, John F. Thompson, Helen Rizos, Roger S. Lo, Richard F. Kefferd, Richard A. Scodyer, and Georgina V. Long

Acknowledgment to Reviewers

ABOUT THE COVER
Olfactomedin-like 3 (Olfm3), a proangiogenic cue and a BMP4 agonist, is produced by both tumor endothelial cells and accompanying pericytes and deposited in the perivascular compartment. Blocking Olfm3 regresses the tumor vasculature, decreases pericyte coverage, and inhibits the progression of tumors. Olfm3 blockade provides an alternative strategy to control tumor growth by targeting a single molecule that affects two distinct cell types within the tumor microenvironment. For details, see article by Miljkovic-Licina and colleagues on page 2588.